This anticipated growth represents an 85% to 89% increase compared to the same period last year. Chief Executive Arun Menawat attributed the upbeat outlook to robust commercial momentum, noting that both new clients and the existing customer base are driving adoption of the company's medical technology.

Before this rally, the stock had struggled throughout the year, closing Wednesday down 28% year to date. The current surge marks a critical shift for the medical device firm as it seeks to stabilize its market position through sustained sales growth.